换一批摘要Currently,the standard clinical practice involves the predominant use of androgen deprivation therapy to treat advanced prostate cancer(PCa),which often inevitably progresses into castration-resistant PCa[1].Because of its unfavorable prognosis and limited treatment alternatives,studies have emphasized the pressing requirement for novel therapeutic targets to enhance the efficacy of advanced PCa treatment and prolong patient survival.
更多相关知识
关键词
Prostate cancer(PCa)ADP-dependent glucokinase(ADPGK)Aldolase CAMP-activated protein kinase(AMPK)Glycolysis
栏目名称
DOI
10.1186/s40779-024-00518-7
发布时间
2025-05-26（万方平台首次上网日期，不代表论文的发表时间）
- 浏览2
- 被引0
- 下载1
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
